All In Biotech

Drug Trial Radar · NCT07692165

A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis

A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants With Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
Jul 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants with Active Ulcerative Colitis. The study aims to evaluate the safety, efficacy, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics of INT-210 in participants with active ulcerative colitis (UC).

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • INT-210 CapsuleDrug

    All participants will receive oral treatment with INT-210 capsule 200 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks).

  • INT-210 CapsuleDrug

    All participants will receive oral treatment with INT-210 capsule 400 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of treatment-emergent adverse eventsTime frame: From enrollment through the safety follow-up visit on Day 92
  2. Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematologyTime frame: From enrollment through the safety follow-up visit on Day 92
  3. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: blood chemistryTime frame: From enrollment through the safety follow-up visit on Day 92
  4. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum ferritinTime frame: From enrollment through the safety follow-up visit on Day 92
  5. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulationTime frame: From enrollment through the safety follow-up visit on Day 92
  6. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysisTime frame: From enrollment through the safety follow-up visit on Day 92
  7. Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)Time frame: From enrollment through the safety follow-up visit on 92
  8. Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)Time frame: From enrollment through the safety follow-up visit on Day 92
  9. Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)Time frame: From enrollment through the safety follow-up visit on Day 92
  10. Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)Time frame: From enrollment through the safety follow-up visit on Day 92
  11. Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)Time frame: From enrollment through the safety follow-up visit on Day 92

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing Luhe Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Guangzhou First People's Hospital

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Shanxi Bethune Hospital

    Taiyuan, China · Recruiting

  • Weifang People's Hospital

    Weifang, China · Recruiting

  • The Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China · Recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, China · Recruiting

  • Xijing Hospital (The First Affiliated Hospital of Air Force Medical University)

    Xi'an, China · Recruiting

  • The First Affiliated Hospital of Henan Medical University

    Xinxiang, China · Recruiting

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.